Disclosed is a (D331Y) PLA2G6 knockin mouse, which shows similar clinical symptoms to those of patients suffering from Parkinson's disease (PD), and begins to display early-onset cell death of dopaminergic neurons in its substantia nigra (SN), synucleinopathy, and tau pathology at the age of about 6 months, wherein the dopaminergic neurons exhibit mitochondrial structural abnormality and dysfunction. Treatment of the (D331Y) PLA2G6 knockin mouse with L-Dopa shows a good response. The (D331Y) PLA2G6 knockin mouse can be used as a platform for developing a medicament and method for treating PD.
EARLY-ONSET PARKINSON'S DISEASE MODEL: (D331Y) PLA2G6 KNOCKIN MODEL, PLATFORM AND METHOD FOR DRUG SCREENING, AND KIT OF DETECTION